Plasma beta amyloid level and depression in older adults

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 1, 2013, Pages 74-79

  Metti, Andrea L ^a   Cauley, Jane A ^a   Newman, Anne B ^a   Ayonayon, Hilsa N ^b   Barry, Lisa C ^c   Kuller, Lewis M ^a   Satterfield, Suzanne ^d   Simonsick, Eleanor M ^e   Yaffe, Kristine ^b,f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Depression; Epidemiology; Plasma beta amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; AGING; ARTICLE; BLOOD; COHORT ANALYSIS; DEMENTIA; DEPRESSION; FEMALE; GENETICS; HUMAN; LONGITUDINAL STUDY; MALE; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; RISK FACTOR; UNITED STATES;

AGED; AGING; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; COHORT STUDIES; DEMENTIA; DEPRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PENNSYLVANIA; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK FACTORS; TENNESSEE;

EID: 84871855448     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls093     Document Type: Article

References (31)

1. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease, and mild cognitive impairment. Findings from the Cardiovascular Health Study. Arch Gen Psychiatry. 2006;63:273-280.
2. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry. 2001;35:776-781.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297:353-356.
4. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippo-campal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63(2): 161-167.
5. Sun X, Bhadelia R, Liebson E, et al. The relationship between plasma amyloid-β peptides and the medial temporal lobe in the homebound elderly. Int J Geriatr Psychiatry. 2010;26:593-601.
6. Blasko I, Kemmler G, Jungwirth S, et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(11):973-982.
7. Moon Y, Kang S, No H, et al. The correlation of plasma Aβ42 levels, depressive symptoms, and cognitive function in the Korean elderly. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1603-1606.
8. Sun X, Steffens DC, Au R, et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry. 2008;65(5):542-550.
9. Sun X, Chiu CC, Liebson E, et al. Depression and plasma amyloid β peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis Assoc Disord. 2009;23:238-244.
10. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma A β42/Aβ 40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354-362.
11. Pesaresi M, Lovati C, Bertora P, et al. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:904-905.
12. Yaffe K, Weston A, Graff-Radford NR, et al. Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305(3):261-266.
13. Yaffe K, Barnes D, Lindquist K, et al. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging. 2007;28:171-178.
14. Slinin Y, Paudel ML, Taylor BC, et al. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology. 2010;74(1):33-41.
15. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401.
16. Beekman AT, Deeg DJ, Van Limbeek J, BraamAW, DeVries MZ, Van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression Scale (CES-D): results from a community-based sample of older subjects in the Netherlands. Psychol Med. 1997;27(1):231-235.
17. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10(2):77-84.
18. Vogelzangs N, Kritchevsky SB, Beekman AT, et al. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry. 2010;71(4):391-399.
19. Erlandsen E, Randers E, Kristensen J. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59:1-8.
20. Hixson J, Vernier D. Restriction isotyping of human apolipoprotein E by gen amplification and cleavage with Hhal. J Lipid Res. 1990; 31(3):545-548.
21. Qiu WQ, Sun X, Selkoe DJ, et al. Depression is associated with low plasma A β 42 independently of cardiovascular disease in the home-bound elderly. Int J Geriatr Psychiatry. 2007;22:536-542.
22. Buckner R, Snyder A, Shannon B, et al. Molecular, structural and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709-7717.
23. Rowe C, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68:1718-1725.
24. Byers A, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7:323-331.
25. Cole J, Costafreda S, McGuffin P, Fu C. Hippocampal atrophy in first episode depression: A meta-analysis of magnetic resonance imaging studies. J Affect Disord. 2011;134:483-487.
26. Martocchia A, Curto M, Toussan L, Stefanelli M, Falaschi P. Pharmacological strategies agains glucocorticoid-mediated brain damage during chronic disorders. Recent Pat CNS Drug Discov. 2011;6:196-204.
27. Kulstad J, McMillan P, Leverenz J, et al. Effects of chronic glucocor-ticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J Neuropathol Exp Neurol. 2005;64(2): 139-146.
28. Irie F, Masaki K, Petrovitch H, et al. Apolipoprotein E e4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the Honolulu-Asia Aging Study. Arch Gen Psychiatry. 2008; 65:906-912.
29. Innogenetics. New Prospects for Research into Alzheimer's Disease with INNO-BIA Plasma A β Forms. A Standardized Research Test for Measuring the Concentrations of Beta-Amyloid Isoforms in Blood. A Literature Review. 2007. http://www.innogenetics.be/documenten/BIA-plasma
30. Alexopoulos GS, Chester JG. Outcomes of geriatric depression. Clin Geriatr Med. 1992;8:363-376.
31. Prince M, Jackson J. World Alzheimer Report. London, UK: Alzheimer's Disease International; 2009.